Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03339401 · ClinicalTrials.gov registry record · Phase 2
The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT03339401 is a Phase 2 study that was terminated before completion, run by Jazz Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT03339401, a Phase 2 study, was terminated before completion, sponsored by Jazz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study was designed to assess the safety, overall tolerability, and antiviral activity of "short course" brincidofovir (BCV) therapy, as compared with current standard of care (SoC), for the treatment of adenovirus (AdV) infections in high-risk (i.e., T cell depleted) pediatric allogeneic hematopoietic cell transplant (HCT) recipients. A virologic response-driven approach to the duration of treatment was to be evaluated, in which subjects randomized to BCV therapy were to be treated until AdV viremia was confirmed as undetectable or until a maximum of 16 weeks of therapy, whichever occurred first. The formulation of BCV used in this study was oral tablet/suspension.
Interventions
- OTHER Standard of Care
- DRUG Brincidofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-12-22 |
| Est. Completion | 2019-05-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03339401
The ClinicalTrials.gov registry entry for NCT03339401 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT03339401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03339401 about?
NCT03339401 is a clinical study titled "The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation". This study was designed to assess the safety, overall tolerability, and antiviral activity of "short course" brincidofovir (BCV) therapy, as compared with current standard of care (SoC), for the treatment of adenovirus (AdV) infections in high-risk (i.e., T cell depleted) pediatric allogeneic hemato...
What is the current status of trial NCT03339401?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2017-12-22. Estimated completion is 2019-05-10.
What interventions are being tested in trial NCT03339401?
The interventions under investigation include: Standard of Care (OTHER), Brincidofovir (DRUG).
Who is sponsoring clinical trial NCT03339401?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.